| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
ALX Oncology Holdings Inc.$2.13
+0.06 (+2.91%)
C 52Pipeline Score Fair Value Biotech · Commercial
Market Cap
266.43 M
EPS
-1.49
P/E Ratio
-
Value Trade
1.21 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
13.61 M
Operating CF
-18.65 M
Total Assets
178.33 M
Total Liabilities
26.98 M
Equity
151.35 M
D/E Ratio
12,345
-1 %
Week
13.79 %
1 Month
-23.55 %
3 Month
46.67 %
6 Month
-96.58 %
5 Year
-94.58 %
All Time
Cash Data
Cash Position
140.32 M
Monthly Burn
6.22 M
Runway
20.7 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
781.67 K
52 Week Range
0.40 - 2.66
% held by Insiders
35.63 %
% held by Institutions
44.05 %
Enterprise Value
139.16 M
Total Shares
134.48 M
Short %
6.83 %
Float Shares
92.52 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for ALX Oncology Holdings Inc.
195Total events
6Upcoming
39Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 6
Oct 2027
T2Timing Guidance
Anticipated important catalysts in next 12-18 months for evorpacept and ALX2004 clinical programs
Oct 2027
T2Timing Guidance
Anticipated important catalysts in next 12-18 months for ALX2004 clinical program
2026-H1
T1Safety Data Update
Initial safety data from ALX2004 Phase 1 program expected in first half of 2026
Event history 189
Q3 2026
◆Interim AnalysisEvorpaceptTrial
Interim data readout from ASPEN-Breast trial
HER2+ Breast Cancersource ↗
May 7, 2026
◆Poster PresentationEvorpaceptPresentation
Exploratory biomarker analysis from phase 1b/2 trial of zanidatamab + evorpacept in HER2-positive mBC presented at ESMO Breast Cancer 2026
HER2-positive metastatic breast cancersource ↗
Apr 13, 2026
◆Management ChangeCorporate
Appointment of Jeff Knight as Chief Development and Operating Officer
Apr 2026
◆Management ChangeCorporate
Appointment of Jeff Knight as Chief Development and Operating Officer
Feb 2026
▼Equity OfferingCorporate
Completed $150 million registered equity offering of common stock and pre-funded warrants
Feb 2026
●Management ChangeCorporate
Barbara Klencke, M.D., appointed permanently as Chief Medical Officer
Jan 30, 2026
▼Equity OfferingCorporate
Pricing of underwritten offering of common stock and pre-funded warrants for gross proceeds of ~$150M
Jan 30, 2026
▲Biomarker DataEvorpaceptClinical Data
Exploratory analysis shows CD47 expression predictive of evorpacept response
HER2-positive breast cancersource ↗
Jan 15, 2026
◆Oral PresentationPresentation
Corporate presentation at 44th Annual J.P. Morgan Healthcare Conference
Drug Pipeline Intelligence
C52
Pipeline Score $344M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored1.3x
rNPV / MCap Top 79%
Micro Cap (rank 192 of 911)
Percentile RankALX Oncology Holdings Inc. carries a moderate pipeline score (52/100), with $3.3B risk-adjusted pipeline value, led by Evorpacept in Metastatic Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| evorpacept Small molecule | Head and Neck Cancer | Phase 2 | NCT04675333 | 19% | $2.9B | ACTIVE NOT_RECRUITING | 361 | FAST | B (63) | Jun 30, 2026 | ELEVATED_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
evorpacept | HER2-positive metastatic breast cancer | Phase 1b/2 | 2026-04-30 | responses were largely restricted to patients with higher CD47 expression Read More | ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 Read More | |
evorpacept | HER2-positive metastatic breast cancer | Phase 1b/2 | 2026-04-30 | responses were largely restricted to patients with higher CD47 expression Read More | ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 Read More | |
evorpacept | HER2-positive metastatic breast cancer | Phase 1b/2 | 2026-04-30 | responses were largely restricted to patients with higher CD47 expression Read More | ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALXO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALXO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALXO▼ -5.9%on this news
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
ALX Oncology has appointed Scott Garland as the new Chairman of the Board, succeeding co-founder Corey Goodman. Garland, who has been a board member since November 2022, is expected to guide the company through its next growth phase. Additionally, Michael Listgarten has been appointed as General Counsel, bringing over 30 years of legal experience in the biopharmaceutical sector.
Read more →ALXO▼ -5.3%on this news· ran to -18% by day 3
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
Read more →ALXO▲ +11.2%on this news
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology reported its Q1 2026 financial results, highlighting promising data from the Phase 1b/2 trial of evorpacept combined with zanidatamab for HER2-positive breast cancer. The company is optimistic about the ongoing ASPEN-09-Breast trial and the ALX2004 Phase 1 trial. Additionally, ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer to enhance its operational capabilities.
Read more →ALXO▼ -10.5%on this newsshared move
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
Read more →ALXO▲ +7.6%on this news· ran to +22% by day 3
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
ALX Oncology announced that data from its Phase 1b/2 trial of evorpacept in combination with zanidatamab for HER2-positive metastatic breast cancer will be presented at the ESMO Breast Cancer 2026 Congress. The presentation will focus on biomarker analyses that suggest CD47 expression may predict treatment response. The company will also report its Q1 2026 financial results shortly after the presentation.
Read more →ALXOALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Read more →ALXO▼ -7.7%on this newsshared move
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
ALX Oncology has appointed Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026. Knight, a veteran in the biopharmaceutical sector, brings over three decades of experience in clinical development and operations. His leadership is expected to enhance ALX's capabilities as the company progresses with its clinical programs, including evorpacept and ALX2004.
Read more →ALXO▼ -10.2%on this news
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ALX Oncology reported its financial results for Q4 and full year 2025, highlighting strong progress in clinical development for its therapies, evorpacept and ALX2004. The company anticipates multiple data sets and milestones in the next 12 to 18 months, supported by a successful $150 million equity offering. Evorpacept shows promise as a predictive biomarker in HER2-positive cancers, while ALX2004 continues to enroll patients in its Phase 1 trial.
Read more →ALXO▲ +12.1%on this news
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
Read more →ALXO▲ +12.1%on this news
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
Read more →ALXO▲ +10.8%on this news· ran to +28% by day 3
ALX Oncology Announces Pricing of Underwritten Offering
ALX Oncology has announced the pricing of an underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $150 million. The offering includes 76,979,112 shares of common stock priced at $1.57 each. The funds will be used to support the clinical development of their lead candidate, evorpacept, and for general corporate purposes. The offering is expected to close on February 2, 2026, pending customary conditions.
Read more →ALXO▲ +10.8%on this news· ran to +28% by day 3shared move
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
ALX Oncology has released new data from a Phase 1b/2 trial indicating that CD47 expression levels can predict the response to evorpacept combined with zanidatamab in HER2-positive metastatic breast cancer patients. The findings support a biomarker-driven approach for optimizing patient selection. The full analysis has been submitted for presentation at an upcoming scientific conference.
Read more →ALXO▲ +8.9%on this news
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
ALX Oncology will participate in the 44th Annual J.P. Morgan Healthcare Conference, where CEO Jason Lettmann and CMO Barbara Klencke will present on January 15, 2026. The company is focused on developing novel cancer therapies, including its lead candidate, evorpacept, which is in multiple clinical trials. ALX2004, another pipeline candidate, is currently in a Phase 1 trial for solid tumors.
Read more →ALXO▲ +8.9%on this news
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
ALX Oncology has initiated the Phase 2 ASPEN-09-Breast trial for evorpacept, targeting HER2-positive metastatic breast cancer. The trial combines evorpacept with trastuzumab and chemotherapy, with interim results expected in Q3 2026. Additionally, the Phase 1 trial for ALX2004 has begun enrolling patients in a third dose cohort, aiming to provide initial safety data in 1H 2026.
Read more →ALXOALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
ALX Oncology announced positive results from a Phase 2 trial of evorpacept combined with rituximab and lenalidomide for patients with indolent B-cell non-Hodgkin lymphoma. The trial reported a 92% complete response rate, significantly higher than the historical 50% for the standard treatment alone. The combination therapy was well-tolerated and demonstrated strong anti-tumor activity, with further evaluations planned for minimal residual disease.
Read more →ALXOALX Oncology to Present at Upcoming Investor Conferences
ALX Oncology to Present at Upcoming Investor Conferences
Read more →ALXO▲ +16.9%on this news
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
ALX Oncology reported its Q3 2025 financial results, highlighting positive data from the ASPEN-06 trial for high CD47-expressing HER2-positive gastric cancer patients treated with evorpacept. The company is advancing its clinical strategy for HER2-positive breast cancer and progressing with the ALX2004 program. Initial safety data from ALX2004 is expected in the first half of next year.
Read more →ALXOALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
ALX Oncology plans to report its Q3 2025 financial results and pipeline updates on November 7, 2025. The company will present data on CD47 as a predictive biomarker for evorpacept in HER2+ gastric cancer at the SITC Annual Meeting. The presentation is part of ongoing efforts to advance their cancer treatment pipeline.
Read more →ALXOALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
ALX Oncology presented promising preclinical data for ALX2004, an EGFR-targeted antibody-drug conjugate, at the 2025 AACR-NCI-EORTC Conference. The ongoing Phase 1 trial aims to evaluate its safety and efficacy in patients with EGFR-expressing solid tumors. Initial safety results are anticipated in the first half of 2026, highlighting its potential to overcome limitations of previous ADCs.
Read more →ALXO▲ +14.1%on this news
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
ALX Oncology announced it will present updated data from its Phase 2 ASPEN-06 trial at the SITC 40th Annual Meeting. The trial evaluates evorpacept in combination with HERCEPTIN and other therapies for HER2-positive gastric cancer. The presentation will highlight CD47 expression as a predictive biomarker, showcasing the potential of evorpacept in treating advanced gastric cancer.
Read more →ALXO▼ -10.2%on this news
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
ALX Oncology has appointed Dr. Barbara Klencke as Interim Chief Medical Officer, succeeding Dr. Alan Sandler, who returns to the Board of Directors. Dr. Klencke brings over 30 years of experience in oncology and has previously contributed to the development of first-in-class therapies. She will lead the execution of ALX's clinical programs, including evorpacept and ALX2004.
Read more →ALXOALX Oncology to Participate in Upcoming Investor Conferences in September
ALX Oncology announced its participation in two upcoming investor conferences in September 2025. The Cantor Global Healthcare Conference will feature a fireside chat and one-on-one meetings, while the H.C. Wainwright Conference will include one-on-one meetings. The company is advancing its cancer therapy pipeline, including lead candidate evorpacept and new candidate ALX2004, which recently entered Phase 1 trials.
Read more →ALXO▼ -8.4%on this news· ran to +21% by day 3
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
ALX Oncology has initiated a Phase 1 clinical trial for ALX2004, an antibody-drug conjugate targeting EGFR-expressing solid tumors. This trial follows positive preclinical data indicating dose-dependent anti-tumor activity and a favorable safety profile. Initial safety data is expected in the first half of 2026, marking a significant step in the development of EGFR-targeted therapies.
Read more →ALXOALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER
ALX Oncology reported strong financial results for Q2 2025, highlighting advancements in their evorpacept and ALX2004 clinical programs. Data from the ASPEN-06 trial indicated that CD47 expression may serve as a predictive biomarker for treatment response in HER2-positive gastric cancer. The company has extended its cash runway into Q1 2027, positioning itself to hit key milestones in its development pipeline. Future studies are being customized based on biomarker findings to optimize patient outcomes.
Read more →ALXO▲ +12.7%on this news
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
Read more →ALXOALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
ALX Oncology will present at the Jefferies 2025 Global Healthcare Conference on June 5, 2025. The company's management will participate in a fireside chat at 1:25 PM ET in New York City. ALX Oncology is focused on developing novel cancer therapies, including evorpacept and ALX2004, which is expected to enter Phase 1 trials soon.
Read more →ALXOALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
Read more →ALXO▲ +10.5%on this news
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
Read more →ALXOALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update – Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D
ALX Oncology reported its financial results for Q1 2025 and provided a corporate update, highlighting a prioritized development strategy for evorpacept. The company will initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 and has received IND clearance for its EGFR-targeted ADC, ALX2004. However, ALX will not pursue a U.S. registrational path for gastric cancer due to FDA feedback, and recent trials showed no advancements for evorpacept with KEYTRUDA. The company has extended its cash runway into Q4 2026, supporting its clinical development plans.
Read more →ALXOALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
Read more →ALXO▼ -9.9%on this news
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
Read more →ALXO▼ -9.9%on this news
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
Read more →ALXOALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
Read more →ALXO▲ +26%on this news
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update – Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong respon
ALX Oncology reported its financial results for the fourth quarter and full year 2024, highlighting positive data from the ASPEN-06 Phase 2 trial for evorpacept in HER2-positive gastric cancer. The company also shared promising results from a Phase 1b/2 trial combining evorpacept with zanidatamab in breast cancer. In response to strategic prioritization, ALX announced a 30% workforce reduction aimed at extending its cash runway into late 2026. Furthermore, key additions to the leadership team were revealed, signifying a potential strategic shift in direction.
Read more →ALXOALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
Read more →ALXOALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Read more →ALXO▲ +7.3%on this news
ALX Oncology to Host Virtual R&D Day on March 5, 2025
ALX Oncology to Host Virtual R&D Day on March 5, 2025
Read more →ALXO▼ -9.4%on this news
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
Read more →ALXO▲ +9.1%on this newsshared move
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors - Mr. Shanth
ALX Oncology has announced key additions to its leadership team, appointing Harish Shantharam as Chief Financial Officer and adding Barbara Klencke and Chris Takimoto to its Board of Directors. These appointments come as the company prepares to advance its lead candidate, evorpacept, into late-stage clinical trials in 2025. The new leaders bring a wealth of experience in oncology drug development and finance, which could bolster ALX's growth strategy and operational effectiveness. The CEO expressed enthusiasm about these strategic hires, which are expected to propel the company's innovation efforts in immuno-oncology.
Read more →ALXO▼ -5.2%on this newsshared move
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
Read more →ALXOALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Read more →ALXOALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
Read more →ALXO▼ -6%on this news· ran to +19% by day 3
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
Read more →ALXO▼ -8.1%on this newsshared move
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
Read more →ALXOALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
Read more →ALXOALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development
ALX Oncology has appointed Dr. Alan Sandler, M.D., as its new Chief Medical Officer. With over 30 years of experience in oncology, Dr. Sandler will focus on advancing the clinical development of ALX's lead compound, evorpacept, into late-stage clinical trials. The company expects 2025 to be a significant year for its operations and growth. Dr. Sandler's extensive background in both clinical development and regulatory affairs positions him as an ideal leader for the company's future endeavors.
Read more →ALXOALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
ALX Oncology reported its financial results for the third quarter of 2024, highlighting significant clinical progress with its lead candidate, evorpacept. The company announced positive topline data from the ASPEN-06 Phase 2 trial, demonstrating evorpacept's efficacy in treating HER2-positive gastric cancer. Furthermore, ALX expects to reach critical clinical milestones soon, supporting its goal of establishing evorpacept as a leading therapeutic option. Financially, net losses reduced compared to the previous year, suggesting improved fiscal health.
Read more →ALXOALX Oncology Announces November Investor Conference Participation
ALX Oncology Announces November Investor Conference Participation
Read more →ALXOALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Read more →ALXO▲ +9.9%on this news
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
Read more →ALXOALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
Read more →ALXOALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
ALX Oncology reported its second quarter 2024 financial results, showcasing advancements in its evorpacept development pipeline. The ASPEN-06 Phase 2 clinical trial presented positive data for evorpacept in treating HER2-positive gastric cancer, with a confirmed overall response rate of 40.3%. Cash reserves are robust, estimated at $186.2 million, supporting operations into 2026. The company anticipates achieving several clinical milestones in the next year.
Read more →ALXOALX Oncology Appoints Alan Sandler, M.D., to Board of Directors ▪ Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development – ▪ Jaume Pons, Ph.D., and Sophia
ALX Oncology has appointed Dr. Alan Sandler to its Board of Directors, effective August 5, 2024. Dr. Sandler, a seasoned veteran in oncology with over 30 years of experience, is expected to contribute significantly to ALX's clinical development, especially regarding its lead candidate evorpacept. His appointment coincides with the company's advancements following positive data from the ASPEN-06 Phase 2 trial. Alongside this change, Jaume Pons and Sophia Randolph have resigned from the Board to concentrate on their leadership roles at ALX.
Read more →ALXO▼ -11.9%on this news· ran to -50% by day 3
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Read more →ALXO▼ -11.9%on this news· ran to -50% by day 3
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
Read more →ALXO▼ -15.7%on this news
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
Read more →ALXO▼ -10.9%on this news· ran to -29% by day 3shared move
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
Read more →ALXOALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
ALX Oncology has reported its first quarter 2024 financial results, highlighting a successful clinical milestone for evorpacept in a Phase 2 trial for HER2-positive gastric cancer. The company also presented positive data from a Phase 1/2 trial in relapsed or refractory B-NHL, demonstrating promising efficacy and safety. Despite a net loss increase to $35.6 million, ALX maintains a strong cash position, expecting to fund operations well into 2026. Upcoming clinical milestones for evorpacept are outlined, including several presentations at the upcoming ASCO meeting.
Read more →ALXO▲ +11.3%on this newsshared move
ALX Oncology Appoints Allison Dillon as Chief Business Officer
ALX Oncology Appoints Allison Dillon as Chief Business Officer
Read more →ALXOALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
Read more →ALXOALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
Read more →ALXOALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Read more →ALXO▲ +10%on this news
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
ALX Oncology reported strong financial results and significant developments for the fourth quarter and full year 2023. The company highlighted positive interim results from the ASPEN-06 Phase 2 clinical trial for evorpacept in advanced gastric cancer, showcasing a promising overall response rate. Additionally, ALX successfully completed an oversubscribed public offering, bolstering its financial position through early 2026. Despite increased research and development expenses and a net loss for the quarter, the company anticipates multiple milestones for evorpacept in 2024.
Read more →ALXOALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
Read more →ALXOALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Read more →ALXO▲ +8.1%on this news
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
ALX Oncology has reported strong financial results for Q3 2023, highlighted by positive interim data from the ASPEN-06 Phase 2 trial of evorpacept in HER2-positive gastric cancer. The company successfully completed a public offering, raising $63.2 million, which will support its clinical programs. Despite these positive developments, ALX reported an increased net loss of $51 million and higher research and development expenses. The company is strategically realigning its leadership to maximize the potential of its maturing pipeline of therapeutic candidates.
Read more →ALXO▲ +16.2%on this news
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Read more →ALXOALX Oncology Announces Pricing of Public Offering
ALX Oncology has priced its public offering of 7,370,690 shares of common stock at $6.38 per share and pre-funded warrants to purchase 1,250,000 shares. The gross proceeds from the offering are anticipated to be around $55 million, which will be allocated towards the clinical development of evorpacept and other corporate purposes. The offering is set to close on or around October 10, 2023, pending customary closing conditions. ALX has also granted underwriters an option to purchase additional shares.
Read more →ALXO▼ -15%on this newsshared move
ALX Oncology Announces Proposed Public Offering
ALX Oncology Announces Proposed Public Offering
Read more →ALXO▲ +56.1%on this news· ran to +74% by day 3shared move
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer Evorpacept is the first CD47 blocker to show activity in a global ran
ALX Oncology has reported positive interim results from its Phase 2 ASPEN-06 clinical trial, evaluating evorpacept in treating advanced HER2-positive gastric cancer. The treatment showed a 52% overall response rate compared to the 22% of standard therapies. Evorpacept is noted as the first CD47 blocker to demonstrate such effectiveness in a global randomized study. The company anticipates reporting final results in Q2 2024 and plans to initiate a Phase 3 study in late 2024.
Read more →ALXOALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Read more →ALXO▲ +6.4%on this news
ALX Oncology Realigns Executive Leadership Team - Jason Lettmann appointed as Chief Executive Officer - Dr. Jaume Pons transitions to Chief Scientific Officer
ALX Oncology has announced a significant realignment of its executive leadership team, appointing Jason Lettmann as the new Chief Executive Officer while Dr. Jaume Pons transitions to the Chief Scientific Officer role. This change is part of the company's strategic evolution as its lead candidate, evorpacept, enters the later stages of clinical development. Lettmann's extensive experience in the biotechnology sector is expected to aid ALX in navigating its clinical trials and business strategies. Pons, as the founder, will continue to focus on the scientific development of evorpacept, which is showing promise in treating various cancers.
Read more →ALXO▲ +6.4%on this news
ALX Oncology Realigns Executive Leadership Team
ALX Oncology Realigns Executive Leadership Team
Read more →ALXOALX Oncology Announces September Investor Conference Participation
ALX Oncology Announces September Investor Conference Participation
Read more →ALXOALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update Advancing Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423 Terminating azacitidine combination deve
ALX Oncology has reported its second quarter financial results and provided updates on its clinical programs, notably advancing the Phase 2/3 ASPEN-06 trial for HER2-positive gastric cancer with data expected by Q4 2023. The company has decided to terminate the ASPEN-02 and ASPEN-05 programs after determining that the combination therapies tested did not provide significant improvements over existing treatments. Despite these terminations, ALX is focusing on developing evorpacept in combination with other anti-cancer therapies, highlighting recent successes such as receiving orphan drug designations in both the U.S. and Europe. Future efforts will include upcoming trials that may substantiate the therapeutic potential of evorpacept.
Read more →ALXOALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer
ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer
Read more →ALXOALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
ALX Oncology reported their Q1 2023 financial results, highlighting advancements in their lead program evorpacept. Notable developments include new clinical trial collaborations with Sanofi and the initiation of several trials for treating various cancers. The company's financial results showed a net loss of $30.2 million but confirmed a robust cash position to support operations through mid-2025. Upcoming clinical readouts in the second half of the year are anticipated to provide further insights into evorpacept's efficacy.
Read more →ALXO▲ +6.4%on this newsshared move
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer
Read more →ALXOALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma
Read more →ALXOALX Oncology and Quantum Leap Healthcare Collaborative Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer
ALX Oncology and Quantum Leap Healthcare Collaborative Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer
Read more →ALXO▼ -5.9%on this newsshared move
ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
ALX Oncology has announced its financial results for the fourth quarter and full year of 2022, highlighting significant advancements in their clinical programs, particularly with evorpacept. The company outlined upcoming milestones for 2023, including data presentations from multiple ongoing trials. Despite strong progress, ALX Oncology reported a substantial net loss and rising research expenses, raising questions about future financial sustainability.
Read more →ALXOALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer
Read more →ALXOALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023
Read more →ALXOALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
Read more →ALXO▲ +5.1%on this news
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia
Read more →ALXO▲ +7.2%on this news
ALX Oncology Appoints Scott Garland to its Board of Directors
ALX Oncology Appoints Scott Garland to its Board of Directors SOUTH SAN FRANCISCO, Calif., November 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ( ALX Oncology ) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoi
Read more →ALXOALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., November 8, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ( ALX Oncology ) (Nasdaq: ALXO), a clinical-stage immuno-oncology
Read more →ALXOALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting
ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting
Read more →ALXOALX Oncology Announces Upcoming Investor Conference Participation
ALX Oncology Announces Upcoming Investor Conference Participation
Read more →ALXOALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept Expects to extend cash runway to mid-2025
ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept Expects to extend cash runway to mid-2025 SOUTH SAN FRANCISCO, Calif., October 31, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings In
Read more →ALXOALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Read more →ALXOALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
Read more →ALXOALX Oncology and Quantum Leap Healthcare Collaborative Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu in Breast Cancer
ALX Oncology and Quantum Leap Healthcare Collaborative Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu in Breast Cancer
Read more →ALXOALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
Read more →ALXOALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., August 8, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ( ALX Oncology ) (Nasdaq: ALXO) a clinical-stage immuno-oncology co
Read more →ALXOALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma
ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma
Read more →ALXOALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia
Read more →ALXOALX Oncology Announces Evorpacept Clinical Program Updates
ALX Oncology Announces Evorpacept Clinical Program Updates
Read more →ALXOALX Oncology to Participate in the Jefferies 2022 Healthcare Conference
ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference
Read more →ALXO▼ -11.5%on this news
ALX Oncology Reports First Quarter 2022 Financial Results an d Provides Clinical Development and Operational Highlights
ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., May 9, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ( ALX Oncology ) (Nasdaq: ALXO) a clinical-stage immuno-oncology compan
Read more →ALXOALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors
ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ( ALX Oncology ) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47
Read more →ALXOALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer
ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer
Read more →ALXO▲ +7.5%on this newsshared move
ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO
Read more →ALXOALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer
Read more →ALXOALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
Read more →ALXO▼ -5.6%on this news
ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference
ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference
Read more →ALXO▼ -24.2%on this news
ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome
ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome
Read more →ALXOALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., November 11, 2021 -- ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO) a clinical-stage immuno-oncology company developin
Read more →ALXO▼ -21.5%on this newsshared move
ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors
ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors
Read more →ALXO▼ -15.5%on this news· ran to -34% by day 3shared move
ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting
ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting
Read more →ALXOALX Oncology Announces Upcoming Virtual Investor Conference Participation
ALX Oncology Announces Upcoming Virtual Investor Conference Participation
Read more →ALXOALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia
ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia
Read more →ALXO▼ -6.7%on this news
ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cy
ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio SOUTH SAN FRANCISCO, Calif., October 7, 2021 -- ALX Oncology Holdings Inc. ("ALX Oncology") (Nasdaq: ALXO), a clinical-stage immuno-oncology company, and ScalmiBio, Inc. ("ScalmiBio") announced toda
Read more →ALXOZymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
Read more →ALXOALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Read more →ALXOALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma
ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma
Read more →ALXOALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights BURLINGAME, Calif., August 12, 2021 -- ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapie
Read more →ALXOALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
Read more →ALXOALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer
Read more →ALXOALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies
ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies
Read more →ALXOALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer
Read more →ALXOALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights BURLINGAME, Calif., May 17, 2021 -- ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies th
Read more →ALXOALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
Read more →ALXOALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer
ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer
Read more →ALXOALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148
ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148
Read more →ALXOALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones BURLINGAME, Calif., March 18, 2021 -- ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO) a clinical-stage immuno
Read more →ALXOALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors
ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors BURLINGAME, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ( ALX Oncology ) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block
Read more →ALXOALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
Read more →ALXOALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference
ALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference
Read more →ALXOALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021
Read more →ALXOALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference
ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference
Read more →ALXOALX Oncology Added to the NASDAQ Biotechnology Index
ALX Oncology Added to the NASDAQ Biotechnology Index
Read more →ALXOALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Read more →ALXOALX Oncology Announces Pricing of Upsized Public Offering of Common Stock
ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock
Read more →ALXOALX Oncology Announces Proposed Public Offering of Common Stock
ALX Oncology Announces Proposed Public Offering of Common Stock
Read more →ALXOALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma
ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma
Read more →ALXOALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies
ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies
Read more →ALXOALX Oncology Announces December 2020 Virtual Investor Conference Participation
ALX Oncology Announces December 2020 Virtual Investor Conference Participation
Read more →ALXOALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights
ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights BURLINGAME, Calif., November 12, 2020 -- ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapi
Read more →ALXOALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
Read more →ALXOALX Oncology to Present ALX148 Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting
ALX Oncology to Present ALX148 Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting
Read more →ALXOALX Oncology Announces November 2020 Virtual Investor Conference Participation
ALX Oncology Announces November 2020 Virtual Investor Conference Participation
Read more →ALXOALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
Read more →ALXOALX Oncology to Present ALX148 Clinical Data at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
ALX Oncology to Present ALX148 Clinical Data at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
Read more →ALXOALX Oncology Names Leading Oncology Experts to Scientific Advisory Board
ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board
Read more →ALXOALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA (pembrolizumab) in Patients with Head & Neck Cancer
ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA (pembrolizumab) in Patients with Head & Neck Cancer
Read more →ALXOALX Oncology Added to Russell 2000 and 3000 Indexes
ALX Oncology Added to Russell 2000 and 3000 Indexes
Read more →ALXOALX Oncology Announces Participation at Upcoming Investor Conferences
ALX Oncology Announces Participation at Upcoming Investor Conferences
Read more →ALXOALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights Completed initial public offering of common stock on
ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights Completed initial public offering of common stock on July 21, 2020, raising gross proceeds of $185.7 million Strengthened leadership team and expanded board of directors
Read more →ALXOALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares
ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares BURLINGAME, Calif. July 21, 2020 ALX Oncology Holdings Inc., (Nasdaq:ALXO) a clinical-stage immuno-oncology company developing therapies that bl
Read more →ALXOALX Oncology Announces Pricing of Initial Public Offering
ALX Oncology Announces Pricing of Initial Public Offering
Read more →Competitive Position
How ALXO ranks across every disease it competes inCompetitive Position is a premium feature
See how ALXO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial